Abstract
Cancer is a systemic disease encompassing multiple components of both tumor cells themselves and host stromal cells. It is now clear that stromal cells in the tumor microenvironment play an important role in cancer development. Molecular events through which reactive stromal cells affect cancer cells can be defined so that biomarkers and therapeutic _targets can be identified. Cancer-associated fibroblasts (CAFs) make up the bulk of cancer stroma and affect the tumor microenvironment such that they promote cancer initiation, angiogenesis, invasion, and metastasis. In breast cancer, CAFs not only promote tumor progression but also induce therapeutic resistance. Accordingly, _targeting CAFs provides a novel way to control tumors with therapeutic resistance. This review summarizes the current understandings of tumor stroma in breast cancer with a particular emphasis on the role of CAFs and the therapeutic implications of CAFs. In addition, the effects of other stromal components such as endothelial cells, macrophages, and adipocytes in breast cancer are also discussed. Finally, we describe the biologic markers to categorize patients into a specific and confirmed subtype for personalized treatment.
Similar content being viewed by others
References
Siegel, R., et al. (2012). Cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 62(1), 10–29.
Paget, S. (1989). The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Reviews, 8(2), 98–101.
Kalluri, R., et al. (2006). Fibroblasts in cancer. Nature Reviews. Cancer, 6(5), 392–401.
Ostman, A., et al. (2009). Cancer-associated fibroblasts and tumor growth—bystanders turning into key players. Current Opinion in Genetics and Development, 19(1), 67–73.
Loeffler, M., et al. (2006). _targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. The Journal of Clinical Investigation, 116(7), 1955–1962.
Gabbiani, G., et al. (1971). Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia, 27(5), 549–550.
Dvorak, H. F. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New England Journal of Medicine, 315(26), 1650–1659.
Kojima, Y., et al. (2010). Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proceedings of the National Academy of Sciences of the United States of America, 107(46), 20009–20014.
Moskovits, N., et al. (2006). p53 attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Research, 66(22), 10671–10676.
Aboussekhra, A. (2011). Role of cancer-associated fibroblasts in breast cancer development and prognosis. International Journal of Developmental Biology, 55(7–9), 841–849.
Kiaris, H., et al. (2005). Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Research, 65(5), 1627–1630.
Trimis, G., et al. (2008). Expression of p21waf1/Cip1 in stromal fibroblasts of primary breast tumors. Human Molecular Genetics, 17(22), 3596–3600.
Trimboli, A. J., et al. (2009). Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature, 461(7267), 1084–1091.
Trimmer, C., et al. (2011). Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: a new genetically tractable model for human cancer associated fibroblasts. Cancer Biology & Therapy, 11(4), 383–394.
Hill, R., et al. (2005). Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell, 123(6), 1001–1011.
Spaeth, E. L., et al. (2009). Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One, 4(4), e4992.
Jotzu, C., et al. (2010). Adipose tissue-derived stem cells differentiate into carcinoma-associated fibroblast-like cells under the influence of tumor-derived factors. Analytical Cellular Pathology (Amsterdam), 33(2), 61–79.
Zeisberg, E. M., et al. (2007). Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Research, 67(21), 10123–10128.
Garin-Chesa, P., et al. (1990). Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody _target in human epithelial cancers. Proceedings of the National Academy of Sciences of the United States of America, 87(18), 7235–7239.
Erez, N., et al. (2010). Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell, 17(2), 135–147.
Mercier, I., et al. (2008). Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: implications for the response to hormonal therapy. Cancer Biology & Therapy, 7(8), 1212–1225.
Sugimoto, H., et al. (2006). Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biology & Therapy, 5(12), 1640–1646.
Perou, C. M., et al. (2000). Molecular portraits of human breast tumours. Nature, 406(6797), 747–752.
Haque, R., et al. (2012). PS1-05: disparities in breast cancer survival by molecular subtype and race/ethnicity. Clinical Medicine & Research, 10(3), 145.
Onitilo, A. A., et al. (2009). Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clinical Medicine & Research, 7(1–2), 4–13.
Martinez-Outschoorn, U. E., et al. (2010). Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle, 9(12), 2423–2433.
Lohr, M., et al. (2001). Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Research, 61(2), 550–555.
Bronzert, D. A., et al. (1987). Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proceedings of the National Academy of Sciences of the United States of America, 84(16), 5763–5767.
Shao, Z. M., et al. (2000). Human breast carcinoma desmoplasia is PDGF initiated. Oncogene, 19(38), 4337–4345.
Strutz, F., et al. (2000). Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney International, 57(4), 1521–1538.
Giannoni, E., et al. (2010). Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial–mesenchymal transition and cancer stemness. Cancer Research, 70(17), 6945–6956.
Hugo, H. J., et al. (2012). Contribution of fibroblast and mast cell (afferent) and tumor (efferent) IL-6 effects within the tumor microenvironment. Cancer Microenvironment. doi:10.1007/s12307-012-0098-7
Koleske, A. J., et al. (1995). Reduction of caveolin and caveolae in oncogenically transformed cells. Proceedings of the National Academy of Sciences of the United States of America, 92(5), 1381–1385.
Martinez-Outschoorn, U. E., et al. (2010). Oxidative stress in cancer associated fibroblasts drives tumor–stroma co-evolution: a new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle, 9(16), 3256–3276.
Al-Ansari, M. M., et al. (2012). p16(INK4A) represses the paracrine tumor-promoting effects of breast stromal fibroblasts. Oncogene. doi:10.1038/onc.2012.270
Serrano, M., et al. (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366(6456), 704–707.
Ohtani, N., et al. (2004). The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. The Journal of Medical Investigation, 51(3–4), 146–153.
Matros, E., et al. (2005). BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Research and Treatment, 91(2), 179–186.
Hasebe, T., et al. (2001). Highly proliferative fibroblasts forming fibrotic focus govern metastasis of invasive ductal carcinoma of the breast. Modern Pathology, 14(4), 325–337.
Orimo, A., et al. (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell, 121(3), 335–348.
Saito, R. A., et al. (2010). Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer. Cancer Research, 70(7), 2644–2654.
Zhang, C., et al. (2009). Fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma. Clinical Cancer Research, 15(12), 4017–4027.
Shekhar, M. P., et al. (2001). Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Research, 61(4), 1320–1326.
Sadlonova, A., et al. (2005). Breast fibroblasts modulate epithelial cell proliferation in three-dimensional in vitro co-culture. Breast Cancer Research, 7(1), R46–R59.
Adams, E. F., et al. (1988). Effects of human breast fibroblasts on growth and 17 beta-estradiol dehydrogenase activity of MCF-7 cells in culture. Breast Cancer Research and Treatment, 11(2), 165–172.
Stuelten, C. H., et al. (2010). Transient tumor–fibroblast interactions increase tumor cell malignancy by a TGF-beta mediated mechanism in a mouse xenograft model of breast cancer. PLoS One, 5(3), e9832.
Hu, M., et al. (2009). Role of COX-2 in epithelial–stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proceedings of the National Academy of Sciences of the United States of America, 106(9), 3372–3377.
Hu, M., et al. (2008). Regulation of in situ to invasive breast carcinoma transition. Cancer Cell, 13(5), 394–406.
Tsuyada, A., et al. (2012). CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Research, 72(11), 2768–2779.
Qian, B. Z., et al. (2011). CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature, 475(7355), 222–225.
Tan, W., et al. (2011). Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature, 470(7335), 548–553.
Rossi, D., et al. (2000). The biology of chemokines and their receptors. Annual Review of Immunology, 18, 217–242.
Roodman, G. D. (2004). Mechanisms of bone metastasis. The New England Journal of Medicine, 350(16), 1655–1664.
Azim, H. A., et al. (2012). Bone metastasis in breast cancer: the story of RANK-ligand. Journal of the Egyptian National Cancer Institute, 24(3), 107–114.
Chen, J., et al. (2011). CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell, 19(4), 541–555.
Campbell, I., et al. (2009). Clonal mutations in the cancer-associated fibroblasts: the case against genetic coevolution. Cancer Research, 69(17), 6765–6768. discussion 6769.
Hu, M., et al. (2005). Distinct epigenetic changes in the stromal cells of breast cancers. Nature Genetics, 37(8), 899–905.
Allinen, M., et al. (2004). Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell, 6(1), 17–32.
Enkelmann, A., et al. (2011). Specific protein and miRNA patterns characterise tumour-associated fibroblasts in bladder cancer. Journal of Cancer Research and Clinical Oncology, 137(5), 751–759.
Fiegl, H., et al. (2006). Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Research, 66(1), 29–33.
Jiang, L., et al. (2008). Global hypomethylation of genomic DNA in cancer-associated myofibroblasts. Cancer Research, 68(23), 9900–9908.
Yu, J., et al. (2012). Unlike pancreatic cancer cells pancreatic cancer associated fibroblasts display minimal gene induction after 5-aza-2′-deoxycytidine. PLoS One, 7(9), e43456.
Robinson, C. M., et al. (2012). Hypoxia-induced DNA hypermethylation in human pulmonary fibroblasts is associated with thy-1 promoter methylation and the development of a pro-fibrotic phenotype. Respiratory Research, 13(1), 74.
Knower, K. C., et al. (2010). Epigenetic mechanisms regulating CYP19 transcription in human breast adipose fibroblasts. Molecular and Cellular Endocrinology, 321(2), 123–130.
Tyan, S. W., et al. (2012). Breast cancer cells induce stromal fibroblasts to secrete ADAMTS1 for cancer invasion through an epigenetic change. PLoS One, 7(4), e35128.
Gangaraju, V. K., et al. (2009). MicroRNAs: key regulators of stem cells. Nature Reviews Molecular Cell Biology, 10(2), 116–125.
Fazi, F., et al. (2008). MicroRNA: basic mechanisms and transcriptional regulatory networks for cell fate determination. Cardiovascular Research, 79(4), 553–561.
Leung, A. K., et al. (2006). Function and localization of microRNAs in mammalian cells. Cold Spring Harbor Symposia on Quantitative Biology, 71, 29–38.
Tiscornia, G., et al. (2010). MicroRNAs in embryonic stem cell function and fate. Genes & Development, 24(24), 2732–2741.
Davis-Dusenbery, B. N., et al. (2010). MicroRNA in cancer: the involvement of aberrant microRNA biogenesis regulatory pathways. Genes Cancer, 1(11), 1100–1114.
Farazi, T. A., et al. (2011). MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Research, 71(13), 4443–4453.
Iliopoulos, D., et al. (2009). An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell, 139(4), 693–706.
Iliopoulos, D., et al. (2010). STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Molecular Cell, 39(4), 493–506.
Iorio, M. V., et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Research, 65(16), 7065–7070.
Jazbutyte, V., et al. (2010). MicroRNA-21: from cancer to cardiovascular disease. Current Drug _targets, 11(8), 926–935.
Qian, B., et al. (2009). High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Research and Treatment, 117(1), 131–140.
Aprelikova, O., et al. (2012). Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility. Oncogene. doi:10.1038/onc.2012.351
Aprelikova, O., et al. (2010). The role of miR-31 and its _target gene SATB2 in cancer-associated fibroblasts. Cell Cycle, 9(21), 4387–4398.
Musumeci, M., et al. (2010). Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene, 30(41), 4231–4242.
Martinez-Outschoorn, U. E., et al. (2011). Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biology & Therapy, 12(10), 924–938.
Sun, Y., et al. (2012). Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nature Medicine. doi:10.1038/nm.2890
Tchou, J., et al. (2012). _targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigm. Advances in Pharmacology, 65, 45–61.
Davies, C., et al. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378(9793), 771–784.
Shekhar, M. P., et al. (2007). Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. American Journal of Pathology, 170(5), 1546–1560.
Pontiggia, O., et al. (2012). The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through beta1 integrin. Breast Cancer Research and Treatment, 133(2), 459–471.
Mueller, K. L., et al. (2012). Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Breast Cancer Research, 14(4), R104.
Johansson, A. C., et al. (2012). Cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma cells. Molecular Cancer Research, 10(9), 1158–1168.
Dittmer, A., et al. (2011). Mesenchymal stem cells and carcinoma-associated fibroblasts sensitize breast cancer cells in 3D cultures to kinase inhibitors. International Journal of Oncology, 39(3), 689–696.
Capparelli, C., et al. (2012). CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, “fueling” tumor growth via paracrine interactions, without an increase in neo-angiogenesis. Cell Cycle, 11(19).
Bergamaschi, A., et al. (2008). Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. The Journal of Pathology, 214(3), 357–367.
Finak, G., et al. (2008). Stromal gene expression predicts clinical outcome in breast cancer. Nature Medicine, 14(5), 518–527.
Sloan, E. K., et al. (2009). Stromal cell expression of caveolin-1 predicts outcome in breast cancer. American Journal of Pathology, 174(6), 2035–2043.
Pavlides, S., et al. (2009). The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle, 8(23), 3984–4001.
Farmer, P., et al. (2009). A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nature Medicine, 15(1), 68–74.
Ahn, S., et al. (2012). The prognostic significance of tumor-associated stroma in invasive breast carcinoma. Tumour Biology, 33, 1573–1580.
Martinet, L., et al. (2011). Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Research, 71(17), 5678–5687.
DeNardo, D. G., et al. (2011). Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discovery, 1(1), 54–67.
Laoui, D., et al. (2011). Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. International Journal of Developmental Biology, 55(7–9), 861–867.
Lee, A. H., et al. (1997). Angiogenesis and inflammation in invasive carcinoma of the breast. Journal of Clinical Pathology, 50(8), 669–673.
Campbell, M. J., et al. (2011). Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Research and Treatment, 128(3), 703–711.
Leek, R. D., et al. (1996). Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Research, 56(20), 4625–4629.
Lewis, C. E., et al. (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Research, 66(2), 605–612.
Lewis, J. S., et al. (2000). Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. The Journal of Pathology, 192(2), 150–158.
Dirkx, A. E., et al. (2006). Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. Journal of Leukocyte Biology, 80(6), 1183–1196.
Roland, C. L., et al. (2009). Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Molecular Cancer Therapeutics, 8(7), 1761–1771.
Melani, C., et al. (2007). Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Research, 67(23), 11438–11446.
Lin, E. Y., et al. (2001). Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. The Journal of Experimental Medicine, 193(6), 727–740.
Oosterling, S. J., et al. (2005). Macrophages direct tumour histology and clinical outcome in a colon cancer model. The Journal of Pathology, 207(2), 147–155.
Mukhtar, R. A., et al. (2011). Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Review of Molecular Diagnostics, 11(1), 91–100.
Nilsson, S., et al. (2012). Downregulation of miR-92a is associated with aggressive breast cancer features and increased tumour macrophage infiltration. PLoS One, 7(4), e36051.
Yang, M., et al. (2011). Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Molecular Cancer, 10, 117.
Hiraoka, K., et al. (2008). Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Science, 99(8), 1595–1602.
Gazzaniga, S., et al. (2007). _targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. The Journal of Investigative Dermatology, 127(8), 2031–2041.
Zeisberger, S. M., et al. (2006). Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. British Journal of Cancer, 95(3), 272–281.
Zhang, W., et al. (2010). Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clinical Cancer Research, 16(13), 3420–3430.
Veltman, J. D., et al. (2010). Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. British Journal of Cancer, 103(5), 629–641.
Luckman, S. P., et al. (1998). Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. Journal of Bone and Mineral Research, 13(11), 1668–1678.
Cecchini, M. G., et al. (1987). Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. Journal of Bone and Mineral Research, 2(2), 135–142.
Coscia, M., et al. (2010). Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by _targeting the mevalonate pathway. Journal of Cellular and Molecular Medicine, 14(12), 2803–2815.
Man, Y. G., et al. (2004). The significance of focal myoepithelial cell layer disruptions in human breast tumor invasion: a paradigm shift from the “protease-centered” hypothesis. Experimental Cell Research, 301(2), 103–118.
Knutson, K. L., et al. (2006). IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. Journal of Immunology, 177(1), 84–91.
Mahmoud, S. M., et al. (2011). Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. Journal of Clinical Oncology, 29(15), 1949–1955.
Ruffell, B., et al. (2012). Leukocyte composition of human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 109(8), 2796–2801.
Acharyya, S., et al. (2011). A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell, 150(1), 165–178.
Iyengar, P., et al. (2005). Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. The Journal of Clinical Investigation, 115(5), 1163–1176.
Iyengar, P., et al. (2003). Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene, 22(41), 6408–6423.
Finley, D. S., et al. (2009). Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. Journal of Urology, 182(4), 1621–1627.
Yu, J. M., et al. (2008). Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells and Development, 17(3), 463–473.
Walter, M., et al. (2009). Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene, 28(30), 2745–2755.
Welte, G., et al. (2012). Interleukin-8 derived from local tissue-resident stromal cells promotes tumor cell invasion. Molecular Carcinogenesis, 51, 861–868.
Pinilla, S., et al. (2009). Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Letters, 284(1), 80–85.
Devarajan, E., et al. (2011). Epithelial–mesenchymal transition in breast cancer lines is mediated through PDGF-D released by tissue-resident stem cells. International Journal of Cancer, 131(5), 1023–1031.
Muehlberg, F. L., et al. (2009). Tissue-resident stem cells promote breast cancer growth and metastasis. Carcinogenesis, 30(4), 589–597.
Bochet, L., et al. (2011). Cancer-associated adipocytes promotes breast tumor radioresistance. Biochemical and Biophysical Research Communications, 411(1), 102–106.
Ligibel, J. (2011). Obesity and breast cancer. Oncology (Williston Park, N.Y.), 25(11), 994–1000.
Dirat, B., et al. (2010). Unraveling the obesity and breast cancer links: a role for cancer-associated adipocytes? Endocrine Development, 19, 45–52.
Harris, R. E., et al. (2009). Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology, 17(2), 55–67.
Dougall, W. C., et al. (2012). Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clinical Cancer Research, 18(2), 326–335.
Acknowledgments
We apologize to the many authors whose excellent work we could not cite owing to space limitation. Research in the authors’ laboratory is supported by National Natural funding of China (81272404, 81071747, 81202087, 81172520), National Key Program (973) for Basic Research of China (2011CB510106, 2011CB504300), Shanghai Education Committee Key Discipline and Specialties Foundation (J50208), the Program for Professor of Special Appointment (Eastern Scholar to J. Wang) at Shanghai Institutions of Higher Learning, and Shanghai Pujiang Program (10PJ1406400), Shanghai Committee of Science and Technology (11DZ2260200), and the Program of Shanghai Municipal Health Bureau Subject Chief Scientist (XBR20110052), National Institutes of Health grant P01 CA093900. This research was supported in part by the grants from Leading Academic Discipline Project of Shanghai Municipal Education Commission (Grant Number: J50208); National Natural Science Foundation of China (Grant Number: 81202087; 81172520).
Conflict of interest statement
The authors declare that there are no conflicts of interest.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Mao, Y., Keller, E.T., Garfield, D.H. et al. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 32, 303–315 (2013). https://doi.org/10.1007/s10555-012-9415-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10555-012-9415-3